Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glucose Tolerance Study
Sponsor: RDC Clinical Pty Ltd
Summary
The goal of this clinical trial is to assess whether TRPTI (oleoylethanolamide) can improve glucose tolerance in healthy adults aged 18 years and above with BMI 18.5-29.9 kg/m². The main questions it aims to answer are: * Does TRPTI improve glucose tolerance as measured by glucose area under the curve (AUC) from 0-120 minutes following a glucose load? * Does TRPTI reduce peak glucose response and alter the time to peak glucose concentration? * Are there dose-dependent effects between 150 mg and 300 mg doses of TRPTI? Researchers will compare TRPTI 150 mg, TRPTI 300 mg, and placebo in a crossover design to see if TRPTI improves glucose metabolism and insulin sensitivity compared to placebo. Participants will complete 3 clinic visits (each lasting approximately 4 hours) with a minimum 6-day washout period between visits.
Official title: A Randomised, Double-blind, Placebo-controlled Crossover Study to Assess the Effect of TRPTI (Oleoylethanolamide) on Glucose Tolerance in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-03
Completion Date
2027-03
Last Updated
2026-02-17
Healthy Volunteers
Yes
Conditions
Interventions
TRPTI 150mg
Single dose of 150mg TRPTI will be orally administered.
TRPTI 300mg
Single dose of 300mg TRPTI will be orally administered.
Placebo
Single dose of placebo will be orally administered.
Locations (1)
RDC Clinical
Brisbane, Queensland, Australia